Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

可威 - NMPA Drug Approval Details

Approvals/NMPA/Oseltamivir Phosphate Capsules

Approved

化学药品

Oseltamivir Phosphate Capsules

宜昌东阳光长江药业股份有限公司🇨🇳 National Medical Products Administration

Approval Date: May 17, 2021
Approval ID: 84cu7SpEGRy
Company: 宜昌东阳光长江药业股份有限公司
Type: 化学药品

Approval Details

Approval Id: 84cu7SpEGRy
Approval Number: 国药准字H20217019
Generic Name: 磷酸奥司他韦胶囊
Generic Name En: Oseltamivir Phosphate Capsules
Trade Name: 可威
Drug Type: 化学药品
Dosage Form: 胶囊剂
Strength: 30mg（按C₁₆H₂₈N₂O₄计）
Reg Date: 2021-05-17
Company Name: 宜昌东阳光长江药业股份有限公司
Company Address: 湖北省宜昌宜都市滨江路38号
Production Company Name: 宜昌东阳光长江药业股份有限公司
Production Company Address: 湖北省宜昌宜都市滨江路38号
Company Detail Path: /organization/hec-cj-pharm
Production Company Detail Path: /organization/hec-cj-pharm

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

May 17, 2021

Approval ID

84cu7SpEGRy

Type

化学药品

Back to NMPA Approvals